Are statins a viable option for the treatment of infections with the hepatitis C virus?

Antiviral Research

Volumn 105, Issue 1, 2014, Pages 92-99

  Verpaalen, Ben ^a   Neyts, Johan ^a   Delang, Leen ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiviral therapy; Cholesterol; Combination therapy; Hepatitis C virus (HCV); Host targeting antivirals; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; CELL PROTEIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; RIBAVIRIN; ANTIVIRUS AGENT; HYPOCHOLESTEROLEMIC AGENT; ATORVASTATIN; BOCEPREVIR; COMPACTIN; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; MEVINOLIN; PEGINTERFERON ALPHA; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TELAPREVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG COST; DRUG RESPONSE; DRUG SAFETY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; LIVER DISEASE; LIVER TOXICITY; META ANALYSIS (TOPIC); MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPLICON; RETROSPECTIVE STUDY; REVIEW; RNA REPLICATION; SIDE EFFECT; SUICIDAL IDEATION; VIRUS INHIBITION; VIRUS REPLICATION; DRUG COMBINATION; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPACIVIRUS; HEPATITIS C, CHRONIC; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; CLINICAL TRIAL; NOTE;

ANTICHOLESTEREMIC AGENTS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; RIBAVIRIN; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84896902734     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.02.020     Document Type: Note

References (80)

1. F. Amemiya, S. Maekawa, Y. Itakura, A. Kanayama, A. Matsui, S. Takano, T. Yamaguchi, J. Itakura, T. Kitamura, T. Inoue, M. Sakamoto, K. Yamauchi, S. Okada, A. Yamashita, N. Sakamoto, M. Itoh, and N. Enomoto Targeting lipid metabolism in the treatment of hepatitis C virus infection J. Infect. Dis. 197 2008 361 370
2. T. Amet, M. Nonaka, M.Z. Dewan, Y. Saitoh, X. Qi, S. Ichinose, N. Yamamoto, and S. Yamaoka Statin-induced inhibition of HIV-1 release from latently infected U1 cells reveals a critical role for protein prenylation in HIV-1 replication Microbes Infect. 10 2008 471 480
3. M. Atsukawa, A. Tsubota, C. Kondo, N. Itokawa, Y. Narahara, K. Nakatsuka, S. Hashimoto, T. Fukuda, Y. Matsushita, H. Kidokoro, T. Kobayashi, H. Kanazawa, and C. Sakamoto Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b J. Gastroenterol. Hepatol. 28 2013 51 56
4. T. Bader, J. Fazili, M. Madhoun, C. Aston, D. Hughes, S. Rizvi, K. Seres, and M. Hasan Fluvastatin inhibits hepatitis C replication in humans Am. J. Gastroenterol. 103 2008 1383 1389
5. D. Burger, D. Back, P. Buggisch, M. Buti, A. Craxí, G. Foster, H. Klinker, D. Larrey, I. Nikitin, S. Pol, M. Puoti, M. Romero-Gómez, H. Wedemeyer, and S. Zeuzem Clinical management of drug-drug interactions in HCV therapy: challenges and solutions J. Hepatol. 58 2013 792 800
6. M.G. Carta, J. Angst, M.F. Moro, G. Mura, M.C. Hardoy, C. Balestrieri, L. Chessa, G. Serra, M.E. Lai, and P. Farci Association of chronic hepatitis C with recurrent brief depression J. Affect. Disord. 141 2012 361 366
7. A. Causevic-Ramosevac, and S. Semiz Drug interactions with statins Acta Pharm. 63 2013 277 293
8. B. Chauvin, S. Drouot, A. Barrail-Tran, and A.-M. Taburet Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors Clin. Pharmacokinet. 52 2013 815 831
9. P.J. Clark, A.J. Thompson, D.M. Vock, L.E. Kratz, A.A. Tolun, A.J. Muir, J.G. McHutchison, M. Subramanian, D.M. Millington, R.I. Kelley, and K. Patel Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner Hepatology 56 2012 49 56
10. A.T. Clarke, and P.R. Mills Atorvastatin associated liver disease Dig. Liver Dis. 38 2006 772 777
11. S. De Denus, S. Spinler, K. Miller, and A. Peterson Statins and liver toxicity: a meta-analysis Pharmacotherapy 24 2004 584 591
12. G. Del Real, S. Jiménez-Baranda, E. Mira, R.A. Lacalle, P. Lucas, C. Gómez-Moutón, M. Alegret, J.M. Peña, M. Rodríguez-Zapata, M. Alvarez-Mon, C. Martínez-A, and S. Mañes Statins inhibit HIV-1 infection by down-regulating Rho activity J. Exp. Med. 200 2004 541 547
13. L. Delang, J. Paeshuyse, I. Vliegen, P. Leyssen, S. Obeid, D. Durantel, F. Zoulim, A. Op de Beeck, and J. Neyts Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development Hepatology 50 2009 6 16
14. K. Domagalski, M. Pawlowska, A. Tretyn, W. Halota, M. Tyczyno, D. Kozielewicz, and D. Dybowska Association of IL28B polymorphisms with the response to peginterferon plus ribavirin combined therapy in polish patients infected with HCV Genotype 1 and 4 Hepat. Mon. 13 2013 1 8
15. H.M. Elgouhari, C.O. Zein, I. Hanouneh, A.E. Feldstein, and N.N. Zein Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection Dig. Dis. Sci. 54 2009 2699 2705
16. D.S. Fedson Treating influenza with statins and other immunomodulatory agents Antiviral Res. 99 2013 417 435
17. K.A. Forde Do statins reduce hepatitis C RNA titers during routine clinical use? World J. Gastroenterol. 15 2009 5020
18. C.D. Furberg, and B. Pitt Withdrawal of cerivastatin from the world market Curr. Control. Trials Cardiovasc. Med. 2 2001 205 207
19. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, T.J. Urban, E.L. Heinzen, P. Qiu, A.H. Bertelsen, A.J. Muir, M. Sulkowski, J.G. McHutchison, and D.B. Goldstein Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
20. Z.F. Gellad, S.D. Reed, and A.J. Muir Review economic evaluation of direct-acting antiviral therapy in chronic hepatitis C Antivir. Ther. 17 2012 1189 1199
21. K. Gibson, and J.P. Rindone Experience with statin use in patients with chronic hepatitis C infection Am. J. Cardiol. 96 2005 1278 1279
22. J. Giguère, and M. Tremblay Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1 J. Virol. 78 2004 12062 12065
23. T.L. Gower, and B.S. Graham Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro Antimicrob. Agents Chemother. 45 2001 1231 1237
24. S.A. Harrison, L. Rossaro, K.-Q. Hu, K. Patel, H. Tillmann, S. Dhaliwal, D.M. Torres, K. Koury, V.S. Goteti, S. Noviello, C.A. Brass, J.K. Albrecht, J.G. McHutchison, and M.S. Sulkowski Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy Hepatology 52 2010 864 874
25. A. Honda, and Y. Matsuzaki Cholesterol and chronic hepatitis C virus infection Hepatol. Res. 41 2011 697 710
26. C.-S. Hsu, C.-J. Liu, C.-H. Liu, C.-L. Chen, M.-Y. Lai, P.-J. Chen, D.-S. Chen, and J.-H. Kao Metabolic profiles in patients with chronic hepatitis C: a case-control study Hepatol. Int. 2 2008 250 257
27. J.M. Hui, J. Kench, G.C. Farrell, R. Lin, D.E.V. Samarasinghe, C. Liddle, K. Byth, and J. George Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection J. Gastroenterol. Hepatol. 17 2002 873 881
28. M. Ikeda, K.-I. Abe, H. Dansako, T. Nakamura, K. Naka, and N. Kato Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system Biochem. Biophys. Res. Commun. 329 2005 1350 1359
29. M. Ikeda, K. Abe, M. Yamada, H. Dansako, K. Naka, and N. Kato Different anti-HCV profiles of statins and their potential for combination therapy with interferon Hepatology 44 2006 117 125
30. E.S. Istvan, and J. Deisenhofer Structural mechanism for statin inhibition of HMG-CoA reductase Science 292 2001 1160 1164
31. C. Jackel-Cram, L. Qiao, Z. Xiang, R. Brownlie, Y. Zhou, L. Babiuk, and Q. Liu Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway J. Gen. Virol. 91 2010 1388 1395
32. S.B. Kapadia, and F.V. Chisari Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids Proc. Natl. Acad. Sci. USA 102 2005 2561 2566
33. S. Khorashadi, N.K. Hasson, and R.C. Cheung Incidence of statin hepatotoxicity in patients with hepatitis C Clin. Gastroenterol. Hepatol. 4 2006 902 907
34. S.S. Kim, L.F. Peng, W. Lin, W.-H. Choe, N. Sakamoto, N. Kato, M. Ikeda, S.L. Schreiber, and R.T. Chung A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication Gastroenterology 132 2007 311 320
35. N. Kinnman, and R. Hultcrantz Lipid lowering medication and hepatotoxicity J. Intern. Med. 250 2001 183 185
36. J.J. Kiser, J.R. Burton, and G.T. Everson Drug-drug interactions during antiviral therapy for chronic hepatitis C Nat. Rev. Gastroenterol. Hepatol. 10 2013 596 606
37. M. Kohjima, M. Enjoji, T. Yoshimoto, R. Yada, T. Fujino, Y. Aoyagi, N. Fukushima, K. Fukuizumi, N. Harada, M. Yada, M. Kato, K. Kotoh, M. Nakashima, N. Sakamoto, and Y. Tanaka Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C J. Med. Virol. 85 2013 250 260
38. C. Kondo, M. Atsukawa, A. Tsubota, N. Itokawa, T. Fukuda, Y. Matsushita, H. Kidokoro, T. Kobayashi, Y. Narahara, K. Nakatsuka, H. Kanazawa, and C. Sakamoto An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin J. Viral Hepat. 19 2012 615 622
39. I. Konishi, N. Horiike, Y. Hiasa, Y. Tokumoto, T. Mashiba, K. Michitaka, Y. Miyake, S. Nonaka, K. Joukou, B. Matsuura, and M. Onji Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C Hepatol. Res. 37 2007 331 336
40. S. Kurincic, C. Lesnicar, M. Poljak, J. Meglic Volkar, M. Rajter, J. Prah, Z. Baklan, T. Kotar, and M. Maticic Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naïve chronic hepatitis C patients infected with genotypes 1 and 3 Intervirology 57 2014 23 30
41. A.M. Lam, C. Espiritu, S. Bansal, H.M. Micolochick Steuer, C. Niu, V. Zennou, M. Keilman, Y. Zhu, S. Lan, M.J. Otto, and P.A. Furman Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus Antimicrob. Agents Chemother. 56 2012 3359 3368
42. M. Law, and A.R. Rudnicka Statin safety: a systematic review Am. J. Cardiol. 97 2006 52C 60C
43. K. Lee, M. Otgonsuren, Z. Younoszai, H.M. Mir, and Z.M. Younossi Association of chronic liver disease with depression: a population-based study Psychosomatics 54 2013 52 59
44. J.E. Lee, R. van Heeswijk, K. Alves, F. Smith, and V. Garg Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin Antimicrob. Agents Chemother. 55 2011 4569 4574
45. J.H. Li, X. Qian Lao, H.L. Tillmann, J. Rowell, K. Patel, A. Thompson, S. Suchindran, A.J. Muir, J.R. Guyton, S.D. Gardner, J.G. McHutchison, and J.J. McCarthy Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection Hepatology 51 2010 1904 1911
46. T.-I. Lin, O. Lenz, G. Fanning, T. Verbinnen, F. Delouvroy, A. Scholliers, K. Vermeiren, A. Rosenquist, M. Edlund, B. Samuelsson, L. Vrang, H. de Kock, P. Wigerinck, P. Raboisson, and K. Simmen In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor Antimicrob. Agents Chemother. 53 2009 1377 1385
47. S. Liu, A.V. Rodriguez, and M.T. Tosteson Role of simvastatin and methyl-beta-cyclodextrin [corrected] on inhibition of poliovirus infection Biochem. Biophys. Res. Commun. 347 2006 51 59
48. B.A. Malcolm, R. Liu, F. Lahser, S. Agrawal, B. Belanger, R. Chase, F. Gheyas, A. Hart, D. Hesk, C. Jiang, R. Kong, J. Lu, J. Pichardo, A. Prongay, A. Skelton, X. Tong, S. Venkatraman, E. Xia, F.G. Njoroge, N. Butkiewicz, P. Ingravallo, and V. Girijavallabhan SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells Antimicrob. Agents Chemother. 50 2006 1013 1020
49. M. Martínez-Gutierrez, J.E. Castellanos, and J.C. Gallego-Gómez Statins reduce dengue virus production via decreased virion assembly Intervirology 54 2011 202 216
50. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, J. McCone, L.M. Nyberg, W.M. Lee, R.H. Ghalib, E.R. Schiff, J.S. Galati, B.R. Bacon, M.N. Davis, P. Mukhopadhyay, K. Koury, S. Noviello, L.D. Pedicone, C.A. Brass, J.K. Albrecht, and M.S. Sulkowski Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N. Engl. J. Med. 361 2009 580 593
51. L. Milazzo, I. Caramma, C. Mazzali, M. Cesari, M. Olivetti, M. Galli, and S. Antinori Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study J. Antimicrob. Chemother. 65 2010 735 740
52. L. Milazzo, L. Meroni, M. Galazzi, M. Cesari, I. Caramma, G. Marchetti, M. Galli, and S. Antinori Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients J. Viral Hepat. 16 2009 479 484
53. K. Nezasa, K. Higaki, T. Matsumara, K. Inazawa, H. Hasegawa, M. Nakano, and M. Koike Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin Drug Metab. Dispos. 30 2002 1158 1163
54. J.G. O'Leary, J.L. Chan, C.M. McMahon, and R.T. Chung Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial Hepatology 45 2007 895 898
55. J. Paeshuyse, A. Kaul, E. De Clercq, B. Rosenwirth, J.-M. Dumont, P. Scalfaro, R. Bartenschlager, and J. Neyts The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro Hepatology 43 2006 761 770
56. A.K. Parsaik, B. Singh, M. Hassan Murad, K. Singh, S.S. Mascarenhas, M.D. Williams, M.I. Lapid, J.W. Richardson, C.P. West, and T.A. Rummans Statins use and risk of depression: a systematic review and meta-analysis J. Affect. Disord. 2013 1 6
57. K. Patel, R. Jhaveri, J. George, G. Qiang, C. Kenedi, K. Brown, C. Cates, A. Zekry, H.L. Tillmann, L. Elliott, R. Kilaru, J. Albrecht, A. Conrad, and J.G. McHutchison Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C J. Viral Hepat. 18 2011 331 337
58. R.B. Perni, S.J. Almquist, R.A. Byrn, G. Chandorkar, P.R. Chaturvedi, L.F. Courtney, C.J. Decker, K. Dinehart, C.A. Gates, S.L. Harbeson, A. Heiser, G. Kalkeri, E. Kolaczkowski, K. Lin, Y. Luong, B.G. Rao, W.P. Taylor, J.A. Thomson, R.D. Tung, Y. Wei, A.D. Kwong, and C. Lin Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob. Agents Chemother. 50 2006 899 909
59. J. Petit Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis Am. J. Gastroenterol. 98 2003 1150 1154
60. L. Potena, G. Frascaroli, F. Grigioni, T. Lazzarotto, G. Magnani, L. Tomasi, F. Coccolo, L. Gabrielli, C. Magelli, M.P. Landini, and A. Branzi Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells Circulation 109 2004 532 536
61. M.M. Ragheb, N.A. Nemr, R.M. Kishk, M.F. Mandour, M.M. Abdou, K. Matsuura, T. Watanabe, and Y. Tanaka Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4 Liver Int. 2013 1 6
62. G.A. Rao, and P.K. Pandya Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C Gastroenterology 140 2011 144 152
63. M. Romero-Gómez, M. Del Mar Viloria, R.J. Andrade, J. Salmerón, M. Diago, C.M. Fernández-Rodríguez, R. Corpas, M. Cruz, L. Grande, L. Vázquez, P. Muñoz-de-Rueda, P. López-Serrano, A. Gila, M.L. Gutiérrez, C. Pérez, A. Ruiz-Extremera, E. Suárez, and J. Castillo Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 2005 636 641
64. L. Rubbia-Brandt, R. Quadri, K. Abid, E. Giostra, P. Malé, G. Mentha, L. Spahr, J. Zarski, B. Borisch, A. Hadengue, and F. Negro Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3 J. Hepatol. 33 2000 106 115
65. R. Sansone, and L. Sansone Cholesterol quandaries: relationship to depression and the suicidal experience Psychiatry 5 2008 22 34
66. E. Schaefer, and R. Chung HCV and host lipids: an intimate connection Semin. Liver Dis. 33 2013 358 368
67. G.A. Schmidt, J.D. Hoehns, J.L. Purcell, R.L. Friedman, and Y. Elhawi Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir J. Am. Board Fam. Med. 20 2007 411 416
68. L. Serfaty, T. Andreani, P. Giral, N. Carbonell, R. Poupon, and O. Chazouille Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C J. Hepatol. 34 2001 428 434
69. H. Sezaki, F. Suzuki, N. Akuta, H. Yatsuji, T. Hosaka, M. Kobayashi, Y. Suzuki, Y. Arase, K. Ikeda, Y. Miyakawa, and H. Kumada An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads Intervirology 52 2009 43 48
70. D. Siagris, M. Christofidou, G.J. Theocharis, N. Pagoni, C. Papadimitriou, A. Lekkou, K. Thomopoulos, I. Starakis, A.C. Tsamandas, and C. Labropoulou-Karatza Serum lipid pattern in chronic hepatitis C: histological and virological correlations J. Viral Hepat. 13 2006 56 61
71. R. Teixeira, Y.D.A. Nascimento, and D. Crespo Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions Braz. J. Infect. Dis. 17 2013 194 204
72. R. Thomssen, S. Bonk, C. Propfe, K.H. Heermann, H.G. Kochel, and A. Uy Association of hepatitis C virus in human sera with beta-lipoprotein Med. Microbiol. Immunol. 181 1992 293 300
73. K.G. Tolman Defining patient risks from expanded preventive therapies Am. J. Cardiol. 85 2000 15E 19E
74. F.L. Tse, H.T. Smith, F.H. Ballard, and J. Nicoletti Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey Biopharm. Drug Dispos. 11 1990 519 531
75. M. Udina, P. Castellví, J. Moreno-España, R. Navinés, M. Valdés, X. Forns, K. Langohr, R. Solà, E. Vieta, and R. Martín-Santos Interferon-induced depression in chronic hepatitis C J. Clin. Psychiatry 73 2012 1128 1138
76. C. Wang, M. Gale, B.C. Keller, H. Huang, M.S. Brown, J.L. Goldstein, and J. Ye Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication Mol. Cell 18 2005 425 434
77. C. Wang, H. Huang, L. Valera, J.-H. Sun, D.R. O'Boyle, P.T. Nower, L. Jia, D. Qiu, X. Huang, A. Altaf, M. Gao, and R.A. Fridell Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052 Antimicrob. Agents Chemother. 56 2012 1350 1358
78. J. Ye, C. Wang, R. Sumpter, M.S. Brown, J.L. Goldstein, and M. Gale Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation Proc. Natl. Acad. Sci. USA 100 2003 15865 15870
79. Z. Zhang, and Z. Yang HPLC determination of lovastatin in rat tissue Chromatographia 66 2007 487 491
80. Q. Zhu, N. Li, Q. Han, P. Zhang, C. Yang, X. Zeng, Y. Chen, Y. Lv, X. Liu, and Z. Liu Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis Antiviral Res. 98 2013 373 379